| |
Research experience
Since its establishment in 1984, multiple clinical vaccine trials have been conducted in the Centre, namely cholera, rotavirus, varicella, measles, poliomyelitis, malaria vaccines and HPV (Human Papillomavirus) vaccine trials conducted.
More recently, HIV vaccine studies have dominated the Center’s work. Thailand experienced the onset of a massive epidemic of the Acquired Immunodeficiency Syndrome (AIDS) in 1988. One of the major strategic components of the Thai response to the AIDS epidemic was the National Plan for HIV/AIDS Vaccine Development and Evaluation initially adopted in 1992. The aim of this national plan was to construct a comprehensive, well-coordinated, long-term strategy for evaluation of the safety, immunogenicity and efficacy of preventive, therapeutic and perinatal HIV/AIDS vaccines in Thailand. The National Plan was revised in 1999, in collaboration with the Joint United Nations Program on AIDS (UNAIDS). As part of this plan, a series of HIV-vaccine trials have been conducted in Thailand since 1993. Phase I/II safety and immunogenicity trials and a phase III efficacy trial of the MN rgp120 HIV-1 Vaccine (Genentech, Inc.) among injecting drug users (IDUs) in Bangkok, Thailand, were conducted during the period 1995-2003. Currently, research activities include clinical trials of HPV vaccine, HIV Vaccine and Shigella vaccine. We are responsible for the clinical part of the world’s largest efficacy trial of HIV vaccine, involving 16,402 participants in the Eastern Seaboard provinces of Thailand.
|
